Cipla Share Price (CIPLA)
as on 01 Aug 2025, 04:01 PM IST
| Source : NSE
Cipla Stock Performance
as on 01 Aug 2025, 04:01 PM IST
Day's Low
Day's High
₹1,494₹1,549.7
0.59%
Downside
3.12%
Upside
52 Week's Low
52 Week's High
₹1,335₹1,702.0511.17%
Downside
13.26%
Upside
| Market Stats | |
| Previous Close | ₹1,554.60 |
| Open | ₹1,544.00 |
| Volume | 21.10L |
| Upper Circuit | ₹1,710.00 |
| Lower Circuit | ₹1,399.20 |
| Day's Low | ₹1,494 |
| Day's High | ₹1,549.7 |
| 52 Week Low | ₹1,335 |
| 52 Week High | ₹1,702.05 |
| Returns % | |
| 1 Month Return | + 0.35 % |
| 3 Month Return | -1.49 % |
| 1 Year Return | -1.7 % |
| 3 Year Return | + 49.65 % |
| 5 Year Return | + 111.54 % |
Cipla Stock Fundamentals & Key Indicators
Check Cipla market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹1,21,388.85 Cr
Return on Equity (ROE)
17.17
PE Ratio (TTM)
22.5
Return on capital employed (ROCE)
21.4
Industry PE ratio
44.86
Beta (LTM)
0.67
P/B Ratio
3.63
Dividend Yield
1.11
PEG Ratio
1.67
Quarterly Earnings Growth YOY
9.84
EPS (TTM)
65.52
Sector
Pharmaceuticals
Book Value
386.25
Technical Analysis
Bullish
View Technical Analysis
Cipla Stock's Interest Amongst Investors
Cipla Stock Valuation
Track how Cipla P/E has moved over time to understand its valuation trends.
Cipla in the last 5 years
Lowest (18.11x)
March 19, 2020
Today (22.50x)
August 1, 2025
Industry (44.86x)
August 1, 2025
Highest (42.80x)
January 23, 2018
Today’s Price to Earnings Ratio: 22.50x
Cipla Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Cipla.
based on 36 analysts
61.11%
Buy
19.44%
Hold
19.44%
Sell
61.11% of analysts recommend a 'BUY' rating for Cipla. Average target price of ₹1642.5
Source: S&P Global Market Intelligence
Cipla Share Price Target
Get share price movements and forecasts by analysts on Cipla.
Cipla price forecast by 36 analysts
Upside of9.30%
High
₹1812
Target
₹1642.50
Low
₹1280
Cipla target price ₹1642.5, a slight upside of 9.3% compared to current price of ₹1502.8. According to 36 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Cipla revenue growth forecast
Expected growth rate Q1, FY2027:15.50%
Forecast
Actual
Including amortisation and stock based compensations
Cipla EPS growth forecast
EPS estimate Q1, FY2027:
Forecast
Actual
Source: S&P Global Market Intelligence
Cipla Ltd Financial Results
Get the annual and quarterly financial summary of Cipla Ltd, including revenue, profit, loss and more.
Cipla Earnings and Dividends
View detailed summary of the earnings and dividend history of Cipla.
Cipla Ltd Earnings Results
Cipla Ltd’s net profit jumped 10.19% since last year same period to ₹1,297.62Cr in the Q1 2025-2026. On a quarterly growth basis, Cipla Ltd has generated 6.2% jump in its net profits since last 3-months.
Read More about Earnings ResultsCipla Ltd Dividends May,2025
In the quarter ending March 2025, Cipla Ltd has declared dividend of ₹13.00 per share on 13 May 2025 - translating a dividend yield of 1.06%.
Read More about Dividends
Indices Featuring Cipla Stock
Check stock indices that include Cipla.
Cipla Stock Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Cipla.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 29.13% | ||
| Foreign Institutions | 25.19% | ||
| Mutual Funds | 20.4% | ||
| Retail Investors | 16.27% | ||
| Others | 9.02% | 14.96 |
Cipla Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Cipla with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 1,21,388.85 | 22.31% | 0.50 | 5,291 | 27,547 | |
| HOLD | 1,68,877.84 | 28.16% | 0.50 | 2,191 | 9,360 | |
| BUY | 1,24,481.41 | 33.93% | 0.64 | 1,911 | 11,516 | |
| BUY | 51,219.08 | -1.4% | 0.60 | 1,429 | 15,261 | |
| HOLD | 32,597.06 | 1.75% | 0.50 | 698 | 5,616 |
Cipla News & Key Events
Latest news and events in one place to help you make informed investing decisions in Cipla.
Cipla Engages Shareholders and Targets GLP-1 Market - 03 Aug, 2025
Cipla has opened a window for physical share transfers and allotted equity shares under employee schemes. The company is also focusing on GLP-1 therapy opportunities with a strategy tailored for India's market.Cipla Stock Shows Bullish Momentum and Target Increases - 29 Jul, 2025
Cipla's stock is experiencing bullish momentum with multiple analysts raising price targets. ICICI Securities targets Rs 1,800, while Jefferies raises its target to Rs 1,690. The company is expected to offset subdued US sales with new product launches and strong performance in chronic therapy segments.Cipla Stock Shows Positive Momentum - 26 Jul, 2025
Cipla's share price has broken out of a falling channel pattern, indicating a long buildup. With strong support at ₹1,500 and targets of ₹1,600/1,650, the stock shows a positive bias and potential upside.Cipla Reports Strong Q1 FY26 Earnings Growth - 25 Jul, 2025
Cipla's Q1 FY26 results show a 10.2% increase in net profit to ₹1,298 crore, driven by strong performance in generics and consumer health. Revenue rose to ₹6,837 crore. The company anticipates significant opportunities in the GLP-1 drug market as patents expire. Cipla's stock rose by approximately 3% following the earnings announcement.Cipla's Q1FY26 Preview Shows Growth Amid Challenges - 23 Jul, 2025
Cipla is set to announce Q1FY26 earnings with moderate growth expectations. Revenue may rise 5.6% YoY, while profit growth is limited. The company reported strong FY25 results, with Foracort as a top-selling brand. However, profitability faces pressure from muted US sales and pricing challenges.Cipla Invests in iCaltech Innovations for Growth - 21 Jul, 2025
Cipla Ltd has signed agreements to acquire a 20% stake in iCaltech Innovations for ₹5 crore, focusing on expanding its presence in respiratory diagnostics and medical devices.Cipla Strengthens Governance with New Auditor Appointment - 17 Jul, 2025
Cipla Limited appointed BNP & Associates as Secretarial Auditors for five years, approved by shareholders at the 89th AGM. This move is expected to boost investor confidence. Additionally, sell flows from institutions and weaker Q1FY26 earnings expectations were noted.Cipla's Strategic Expansion and Study Completion - 16 Jul, 2025
Cipla is expanding its dermatology product line while completing a significant asthma study, enhancing its market position. Chairman YK Hamied emphasizes future investments and focus areas.Cipla Ventures into Weight Management Market - 13 Jul, 2025
Cipla is set to enter India's weight management market, addressing rising obesity demands while enhancing its central nervous system portfolio through strategic acquisitions and in-licensing deals.
Insights on Cipla Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 2 quarters, 7.01K Cr → 7.21K Cr (in ₹), with an average increase of 2.7% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 1.22K Cr → 1.29K Cr (in ₹), with an average increase of 5.8% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 27.5% return, outperforming this stock by 29.2%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 29.13% of holdings in Jun 2025 quarter
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 142.4% return, outperforming this stock by 92.8%
NEGATIVE IMPACTPrice Dip
In the last 7 days, CIPLA stock has moved down by -4.4%
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 26.22% to 25.19% in Jun 2025 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 20.47% to 20.40% in Jun 2025 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 16.33% to 16.27% in Jun 2025 quarter
About Cipla Ltd
Cipla's operations include manufacturing, marketing, and distribution of pharmaceuticals, biotechnology, and consumer healthcare products. Its top products include respiratory, anti-infectives, cardiovascular, and oncology drugs. Popular brands include Asthalin, Cipcal, Cifran, and Erythromycin. Cipla also manufactures nutraceuticals, herbal products, and over-the-counter medicines.
Revenue: ₹6,837.04Cr as on June 2025 (Q1 FY26)
Net Profit: ₹1,292.05Cr as on June 2025 (Q1 FY26)
Listing date: 03 Nov, 1994
Chairperson Name: Y K Hamied
| Organisation | Cipla Ltd |
| Industry | Pharmaceuticals |
| CEO | Y K Hamied |
| E-voting on shares | Click here to vote |
Mutual Funds that own Cipla Stock
Check out the Mutual Funds with significant holdings in Cipla.
FAQs
What is Cipla share price today?
Cipla share price today stands at ₹1502.8, Open: ₹1544, Previous Close: ₹1554.6, High: ₹1549.7, Low: ₹1494, 52 Week High: ₹1702.05, 52 Week Low: ₹1335 as on 01 Aug 2025, 04:01 PM IST.
How to buy Cipla shares ?
To buy Cipla shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for CIPLA or Cipla Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Cipla shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is today's traded volume of Cipla?
Today's traded volume of Cipla is 21.10L. Which means that 21.10L shares of Cipla were bought and sold on the stock market during today's trading session.
What is Cipla's market cap today?
Today's market capitalisation of Cipla is ₹1,21,388.85 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Cipla?
Cipla’s 52 week high is ₹1702.05 and 52 week low is ₹1335. The current share price of Cipla is ₹1502.8, which is -11.71% down from its 52 week high and 12.57% up from its 52 week low.